

First patients recruited in COVID-19 clinical study in India

- **First patients recruited in Indian study to collect cough sounds from patients with suspected COVID-19**
- **Study aims to recruit 220 participants, with recruitment expected to be complete by the end of October**
- **ResApp aims to use the data to develop a smartphone-based algorithm to instantly screen for COVID-19 as well as monitor disease progression**

Brisbane, Australia, 20 September 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease today announced that it has recruited ten patients on the first day of its pilot study for the collection of cough sounds from patients with suspected COVID-19 in India (refer ASX announcement 9 August 2021). ResApp aims to use this data to develop a smartphone-based algorithm to instantly screen for COVID-19 and monitor disease progression.

Patient recruitment follows approval from an institutional review board that assessed and approved the ethical design of the study. The study is registered on Clinical Trials Registry – India (CTRI/2021/09/036581). ResApp has engaged Triomics, a clinical trial company based in India, to complete the study.

The study will collect cough sounds, symptoms, medical history and a COVID-19 polymerase chain reaction (PCR) test result from each participant. The multi-site study will recruit a total of 220 participants across two study arms: 120 individuals who present for outpatient COVID-19 PCR testing and 100 individuals who are COVID-19 positive and are inpatients at a study site. Inpatients will provide cough sound samples at multiple times during their hospital stay. Study recruitment is expected to be complete by the end of October.

ResApp is using data collected in this clinical study, as well as its two US studies, to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone.

CEO and Managing Director, Dr Tony Keating commented: *"We are excited to have recruited our first patients in our Indian COVID-19 study. We are confident that with this study, our two COVID-Cough studies in the United States, and our existing pre-COVID respiratory disease cough datasets, we are in a unique position to develop smartphone-based tools to instantly screen for COVID-19 as well as build tools to assist healthcare providers effectively manage COVID-19 positive patients, whether in the home or in healthcare facilities."*

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine



learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.